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Abstract
Many neurotoxicants affect energy metabolism in man, but currently available test methods may still fail to predict mito- and 
neurotoxicity. We addressed this issue using LUHMES cells, i.e., human neuronal precursors that easily differentiate into 
mature neurons. Within the NeuriTox assay, they have been used to screen for neurotoxicants. Our new approach is based 
on culturing the cells in either glucose or galactose (Glc–Gal–NeuriTox) as the main carbohydrate source during toxicity 
testing. Using this Glc–Gal–NeuriTox assay, 52 mitochondrial and non-mitochondrial toxicants were tested. The panel 
of chemicals comprised 11 inhibitors of mitochondrial respiratory chain complex I (cI), 4 inhibitors of cII, 8 of cIII, and 
2 of cIV; 8 toxicants were included as they are assumed to be mitochondrial uncouplers. In galactose, cells became more 
dependent on mitochondrial function, which made them 2–3 orders of magnitude more sensitive to various mitotoxicants. 
Moreover, galactose enhanced the specific neurotoxicity (destruction of neurites) compared to a general cytotoxicity (plasma 
membrane lysis) of the toxicants. The Glc–Gal–NeuriTox assay worked particularly well for inhibitors of cI and cIII, while 
the toxicity of uncouplers and non-mitochondrial toxicants did not differ significantly upon glucose ↔ galactose exchange. 
As a secondary assay, we developed a method to quantify the inhibition of all mitochondrial respiratory chain functions/
complexes in LUHMES cells. The combination of the Glc–Gal–NeuriTox neurotoxicity screening assay with the mechanistic 
follow up of target site identification allowed both, a more sensitive detection of neurotoxicants and a sharper definition of 
the mode of action of mitochondrial toxicants.
Keywords Neurotoxicity · Mitotoxicity · Metabolic reprogramming · High-throughput toxicity screening · High content 
imaging · Mechanistic safety assessment
Abbreviations
ADP  Adenosine triphosphate
AOP  Adverse outcome pathway
Asp  l-Aspartate
ATP  Adenosine diphosphate
cAMP  N6,2′-O-Dibutyryladenosine 3′,5′-cyclic 
monophosphate
cI–V  MRC complex I–V
CNS  Central nervous system
Cyt c  Cytochrome c
FAD(H2)  Flavin adenine dinucleotide (FAD: oxi-
dized, FADH2: reduced)
FCCP  Carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone
G6P  Glucose-6-phosphate
Gal1P  Galactose-1-phosphate
GALK  Galactokinase
GALT  Galactose-1-phosphate uridylyltransferase
GDNF  Glial derived neurotrophic factor
Glc1P  Glucose-1-phosphate
Hex  Hexose, in this study either glucose or 
galactose
HK  Hexokinase
Lac  Lactate
Mal  Malate
MoA  Mode of action
MPP  1-Methyl-4-phenylpyridinium
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MRC  Mitochondrial respiratory chain
NA  Neurite area
NAD(H)  Nicotinamide adenine dinucleotide (NAD: 
oxidized, NADH: reduced)
NPA  3-Nitropropionic acid
O2  Oxygen
OA  Oxaloacetate
OCR  Oxygen consumption rate
PC  Pyruvate carboxylase
PGM  Phosphoglucomutase
Pyr  Pyruvate
Q  Ubiquinone or coenzyme Q
ROS  Reactive oxygen species
Ser  l-Serine
SSA  5′-Sulfosalicylic acid
TCA  Citric acid cycle or Krebs cycle or tricarbo-
nic acid cycle
UDP  Uridine diphosphate
UDP-GALE  UDP-glucose 4-epimerase
V  Viability
Introduction
Specific identification of neurotoxicants still remains 
a problem to be solved, and assay conditions need to 
be optimized to increase the sensitivity of the available 
in vitro tests (Schmidt et al. 2017; van Thriel et al. 2017). 
The metabolic situation of a given cell type is one of the 
parameters that may be tuned as it is known to be one 
of the key determinants affecting the type and extent of 
toxicity triggered by a chemical (Delp et al. 2018a; Latta 
et al. 2000; Leist et al. 1997b, 1999; Volbracht et al. 1999). 
Replacement of glucose for galactose in cell culture media 
was reported to tune cellular metabolism from a primary 
glycolytic to a predominantly mitochondrial phenotype 
without impairing ATP production (Reitzer et al. 1979; 
Robinson et al. 1992).
Mitochondria are key organelles of eukaryotic cells, best 
known for their central role in energy homeostasis (Zhang 
and Avalos 2017). However, their failure also affects other 
cell functions, such as calcium signaling (Huang et  al. 
2017; Leist and Nicotera 1998), (phospho)lipid metabolism 
(Wajner and Amaral 2015), neurotransmitter turnover (Leist 
et al. 1998; Nicotera et al. 1999), amino acid metabolism 
including urea generation (Porporato et al. 2016) and steroid 
metabolism (Martin et al. 2016). Mitochondrial dysfunctions 
may therefore have largely different manifestations in differ-
ent tissues and metabolic situations. Moreover, such defects 
may escape detection in commonly used toxicological mod-
els due to the compensatory capacities that are often seen in 
animal models (Blomme and Will 2016). Also, most com-
monly used cell cultures lack sensitivity, as culture media 
contain frequently supra-physiological amounts of glucose, 
and thereby facilitate aerobic glycolysis instead of mitochon-
drial activity for energy production (Jones and Bianchi 2015; 
Lunt and Vander Heiden 2011; Reitzer et al. 1979).
Considering the difficulties of detecting mitochondrial 
toxicity (mitotoxicity) in rodents, it is not surprising that 
many drugs that had to be withdrawn from the market (e.g., 
troglitazone and cerivastatin), had later been linked to mito-
toxicity (Blomme and Will 2016; Tirmenstein et al. 2002; 
Westwood et al. 2005). Indeed, a sizable fraction of com-
pounds causing, e.g., drug-induced liver injury are mitotoxi-
cants (Aleo et al. 2014; Begriche et al. 2011; Pessayre et al. 
2012; Rana et al. 2018; Tilmant et al. 2018).
The need to obtain data on mitochondrial toxicity has 
been realized in several large European research projects 
(Desprez et al. 2018; Dragovic et al. 2016; Jennings et al. 
2014; Kinsner-Ovaskainen et  al. 2013; Kohonen et  al. 
2017; Wolters et al. 2018) as well as by the Tox21 program 
(Attene-Ramos et al. 2015; Xia et al. 2018).
During the past 2 decades, technologies have become 
available that allow the investigation of cellular oxygen con-
sumption for large numbers of samples. Examples are the 
Agilent Seahorse devices, with sensors fixed to dedicated 
plates (Nadanaciva et al. 2012) or various methods using 
soluble sensors to be added to the cell cultures (Gerencser 
et al. 2009; O’Riordan et al. 2007). Optimized protocols 
to permeabilize cells allow detailed studies on individual 
mitochondrial respiratory chain complexes without the need 
to isolate mitochondria from cells (Divakaruni et al. 2014; 
Salabei et al. 2014).
To make cell lines more dependent on mitochondrial 
metabolism, especially the pharmaceutical industry has 
developed the approach of reducing glucose availability in 
test systems like HepG2 hepatoma cells (Blomme and Will 
2016; Kamalian et al. 2015; Marroquin et al. 2007; Will 
and Dykens 2014), mouse embryonal and primary human 
fibroblasts (Pereira et al. 2012, 2018), leukemia K562 cells 
(Swiss et al. 2013), or skeletal muscle cells (Dott et al. 
2014).
For typical cell lines, ≥ 80% of the glucose taken up is 
excreted as lactate, while only 5% is oxidized in mitochon-
dria. In cells that offered galactose (Gal) instead of glucose 
(Glc), glycolytic flux is largely reduced, while mitochon-
drial usage increases to produce sufficient ATP (Reitzer et al. 
1979; Robinson et al. 1992). The original Glc–Gal assays 
used in toxicology, analyze the shift in cytotoxic potency 
of a test compound in glucose vs galactose culture condi-
tions. More recently, the Glc–Gal assay was combined with 
global oxygen consumption measurements of intact cells to 
further verify the impairment of mitochondrial metabolism 
(Eakins et al. 2016). The Glc–Gal shift conditions were also 
exploited to identify vital OXPHOS genes and a regulatory 
network of them (Arroyo et al. 2016; Robinson et al. 1992).
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Neurotoxicity is one of the most frequent drug side effects 
and involves multiple mechanisms (Bal-Price et al. 2015b; 
Budnitz et al. 2006). As neurons are highly mitochondria-
dependent cells, they are particularly susceptible to mito-
chondrial toxicants (Schmidt et al. 2017). Accordingly, some 
of the most notorious neurotoxicants, such as carbon monox-
ide, nitropropionic acid, rotenone and  MPP+ are mitochon-
drial respiratory chain inhibitors (He et al. 2017; Leist et al. 
1997a, c, 1998; Levy 2017; Nicklas et al. 1985; Nicotera and 
Leist 1997; Schildknecht et al. 2017; Sherer et al. 2007). One 
of the few adverse outcome pathways (AOP) fully endorsed 
by the OECD has mitochondrial dysfunction as the pivotal 
key event (Bal-Price et al. 2018; Terron et al. 2018). Given 
this situation, it is surprising that only few toxicological test 
methods focus on the sensitive detection of mitochondrial 
neurotoxicants. Typical neuronal in vitro cultures are fed 
with high glucose concentrations, and galactose assays have 
so far not been established in this area.
To closer explore the role of mitochondria in neurotoxic-
ity, the European research project EU-ToxRisk has initiated 
a case study (designated CS4) which investigates the propen-
sity of various mitochondrial inhibitors to cause neurotoxic-
ity (http://www.eu-toxri sk.eu/). Within this context, a broad 
panel of mitotoxicants was identified as tool compounds to 
trigger mechanistically diverse types of respiratory dysfunc-
tion. This set of compounds (Suppl. Item 1) was used here to 
refine existing human cell-based neurotoxicity assays.
The new approach methods (NAM) currently available to 
test neurotoxicity (Barbosa et al. 2015; Forsby et al. 2009; 
Gustafsson et al. 2010; Harrill et al. 2018; Hendriks et al. 
2014; Schmuck and Kahl 2009; Schultz et al. 2015; Terrasso 
et al. 2015; Wilson et al. 2014) make use of the particu-
lar vulnerability of specific sub-populations (Zimmer et al. 
2011) or they use functional readouts like specific inhibi-
tion of neurite outgrowth (Harrill et al. 2011; Hoelting et al. 
2016; Krug et al. 2013), disturbance of network formation 
(Bal-Price et al. 2015a; Frank et al. 2017) or impaired cal-
cium signaling (Gustafsson et al. 2010; Nordin-Andersson 
et al. 2003). None of these methods is particularly tuned to 
identify mitochondrial neurotoxicants.
Therefore, this study was initiated to modify the 
LUHMES cell-based NeuriTox test (Krug et al. 2013; Stie-
gler et al. 2011) to detect mitochondrial neurotoxicants more 
sensitively. The easy availability of high amounts of well-
controlled neuronal cells makes the LUHMES-based assay 
suitable for high-throughput screening (Delp et al. 2018b; 
Schildknecht et al. 2013). These cells can be differentiated 
homogenously within 5 days into mature neurons (Scholz 
et al. 2011) that show high sensitivity to toxicants (Gutbier 
et al. 2018a, b; Tong et al. 2017, 2018; Witt et al. 2017). The 
conventional NeuriTox test differentiates between blunt cyto-
toxicity and the specific inhibition of neurite outgrowth to 
detect neurotoxicants (Delp et al. 2018b; Krug et al. 2013). 
In this study, the Glc–Gal shift was explored as expansion 
of the test protocol. Moreover, a secondary follow-up assay 
was developed to pinpoint the mode of action of mitotoxi-
cants identified in the new Glc–Gal NeuriTox assay. The link 
of neurotoxicants to their inhibition of specific parts of the 
neuronal mitochondrial respiratory chain can be used for hit 
confirmation of mitotoxicity screens.
Materials and methods
Materials
Unless specified otherwise, cell culture reagents (consuma-
bles and media) were from Gibco/Thermo Fisher Scientific 
(Waltham, USA), and fine chemicals (inhibitors, substrates) 
were from Sigma-Aldrich (Steinheim, GER). Physico-chem-
ical properties, CAS identifiers and literature references of 
the tested set of chemicals are compiled in Suppl. Item 1.
Assessment of neurotoxicity by human neurite 
outgrowth assay (NeuriTox)
LUHMES (Lund human mesencephalic) cells were cul-
tured as previously described (Delp et al. 2018b; Krug et al. 
2013; Stiegler et al. 2011). Briefly, proliferating precursor 
cells were kept in proliferation medium [AdvDMEM/F12 
containing 2 mM l-glutamine, 1 × N2 supplement (Invit-
rogen)] enriched with 40 ng/ml recombinant human basic 
fibroblast growth factor (R+D systems) and cultured in a 
5%  CO2/95% air atmosphere at 37 °C. Cell culture dishes 
and flasks (Sarstedt) were pre-coated with 50 μg/ml poly-
l-ornithine (PLO) and 1 μg/ml fibronectin (Sigma-Aldrich). 
Differentiation to post-mitotic neurons was performed by 
seeding cells at a density of 45,000 cells/cm2 kept in prolif-
eration medium for 24 h and a subsequent medium change 
to differentiation medium [AdvDMEM/F12 supplemented 
with 2 mM l-glutamine, 1 × N2 (Invitrogen), 1 mM N6,2′-
O-dibutyryl 3′,5′-cyclic adenosine monophosphate (cAMP) 
(Sigma-Aldrich), 1 µg/ml tetracycline (Sigma-Aldrich), and 
2 ng/ml recombinant human glial cell-derived neurotrophic 
factor (GDNF, R+D Systems)]. After 48 h of differentiation, 
cells were detached with 0.05% trypsin/EDTA (Invitrogen) 
and seeded into 96 well plates at a density of 100,000 cells/
cm2. In the standard NeuriTox setup, pre-differentiated cells 
were treated 1 h after seeding, i.e., on day 2 of differentia-
tion (d2) for 24 h. For the assessment of neurite area on d2, 
directly before trypsinization, cells were pre-differentiated 
in 96-well plates and assayed after 48 h of differentiation.
1588 Archives of Toxicology (2019) 93:1585–1608
1 3
Glc–Gal NeuriTox assay
For the modified Gal–NeuriTox assay, the cells were handled 
exactly in the same way, but the medium contained 18 mM 
galactose. To assess the difference between cells grown in 
glucose (Glc cells) and cells grown in galactose (Gal cells), 
the same proliferating precursor population was always used 
for parallel differentiations in the presence of either glucose 
(Glc medium) or galactose (Gal medium).
Image acquisition and quantification in the neurite 
assays
Image acquisition was performed exactly as described previ-
ously (Krug et al. 2013; Schildknecht et al. 2013; Stiegler 
et al. 2011). Briefly, cells were live stained with 1 µg/ml 
Hoechst H-33342 and 1 µM calcein-AM for image acquisi-
tion. The neurite area was calculated as the total calcein-
positive area corrected for the somatic area, covered by 
the cell bodies. If cell densities varied from preparation to 
preparation (e.g., for the Glc Gal comparison of d2 cells 
before replating), data were compared between parallel cul-
tures from individual preparations. The apparent neurite area 
per cell was smaller in high-density cultures, since neurites 
growing over cell bodies were excluded by the software. For 
statistical tests, then the pairwise mode was chosen. This 
was necessary as the applied image quantification algorithm 
requires equal cell densities. Viable cells were defined by 
a nucleus with overlapping calcein signal. Nuclei without 
calcein stain were counted as dead cells. Viability was 
expressed as viable cells/total cells × 100%.
Seahorse assessment of mitochondrial 
and glycolytic functional parameters of intact 
LUHMES cells
Assessment of mitochondrial and glycolytic functional-
ity was performed exactly as described earlier (Delp et al. 
2018b). Briefly, d2 LUHMES cells, already cultured for 48 h 
in either Glc medium or Gal medium were seeded at a den-
sity of 100,000 cells/cm2 into Agilent Seahorse XFe24 well 
plates. 24 h later (on d3), cells were analyzed. The “basal” 
respiration and acidification were measured in untreated 
cells; the “maximal respiration” was measured in the pres-
ence of 1.5  µM carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP); the “maximal acidification” was 
assessed in Glc cells in the presence of 1 µM oligomycin, 
which blocked mitochondrial energy production and made 
cells 100% dependent on glycolysis for energy produc-
tion. Due to the different situation in Gal cells (depend-
ence on mitochondria), different conditions were chosen 
here to maximize the galactolytic flux. Mitochondria were 
uncoupled by 1.5 µM FCCP to allow a maximal metabo-
lism of pyruvate which was not secreted as lactate by these 
cells. Under such conditions,  CO2 produced by the TCA 
might contribute to the acidification. Oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) were 
always normalized to the cell count. The latter was obtained 
by including 1 µg/ml H-33342 plus 1 µM calcein-AM (final 
concentrations on the cells) in the last Seahorse injection 
followed by automated image analysis as described above 
for the NeuriTox assay [using the Seahorse assay plates on 
Cellomics CellInsight (Cellomics, Waltham, MA, USA)].
Assessment of the function of individual 
mitochondrial complexes in permeabilized LUHMES 
cells
To study the inhibition of individual mitochondrial respira-
tory chain (MRC) complexes, proliferating LUHMES cells 
were seeded into Agilent Seahorse XFe24 well plates at a 
density of 205,000 or 135,000 cells/cm2 and were allowed 
to grow for 1 or 2 days in proliferation medium, respectively. 
They were used at 24–48 h after seeding, when they had 
recovered from replating and reached 95% confluency, but 
were not overgrown. For the assay, cells were permeabilized 
with MAS buffer (220 mM mannitol, 1 mM ADP, 70 mM 
sucrose, 10 mM  KH2PO4, 5 mM  MgCl2, 2 mM HEPES, 
1 mM EGTA, 4 mg/ml fatty acid-free BSA, pH = 7.2) sup-
plemented with 25 µg/ml digitonin (Salabei et al. 2014). The 
Seahorse measurements of OCR were started 30 min after 
permeabilization. The function of respiratory chain com-
plexes was assessed by a strategy (Salabei et al. 2014) based 
on applying complex-specific substrates and inhibitors, 
with exact conditions optimized to LUHMES [cI: substrate 
was 5 mM Pyr, 2 mM Gln, and 2.5 mM Mal, inhibitor was 
0.5 µM rotenone; cII: substrate was 10 mM succinate, inhibi-
tor was 5 mM malonate; cIII: substrate was 250 µM duro-
quinol (TCI chemicals Germany, Eschborn, GER), inhibi-
tor was 0.5 µM antimycin A; cIV: 125 µM TMPD + 2 mM 
ascorbic acid, no specific inhibitor was used] and the injec-
tion strategy is detailed in the results section as part of the 
seventh figure. Since the measurement was extremely sensi-
tive to cell number variations, the last measurement before 
the injection of the test substance was used for internal nor-
malization. For each respiratory chain complex, its activ-
ity in the presence of solvent control (DMSO) was used as 
reference to normalize the data for samples exposed to test 
substances.
Lactate quantification
To measure the lactate secretion, Glc and Gal cells were 
seeded at d2 into fresh (lactate free) medium and cultured 
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for 24 h. The lactate concentration in the medium was deter-
mined by a commercially available enzymatic assay (Dia-
global LAC142 assay, Berlin, Germany) with a colorimetric 
endpoint. The amount of lactate produced within 24 h was 
normalized to the live cell count. The latter was assessed by 
H-33342 and calcein-AM staining as described above.
Proteasomal activity
To quantify the proteasomal activity, cells were cultured and 
exposed exactly in the same way as for the NeuriTox assay. 
Parallel plates that were not used to assess viability and 
neurite outgrowth were used to assess proteasomal activity. 
Activity measurements were performed exactly as described 
in (Gutbier et al. 2018b). The assay is based on the replace-
ment of cell culture medium by HBSS buffer containing a 
cell permeable proteasomal substrate [MeOSuc-Gly-Leu-
Phe-AMC, 25 µM (Bachem, Bubendorf, Switzerland)] after 
24 h of toxicant exposure. AMC fluorescence (ex: 360 nm, 
em: 465 nm) was determined directly after addition of the 
assay buffer to the cells and after 90 min incubation. The 
increase in fluorescence was used as a measure of protea-
somal activity.
Intracellular ATP
To assess intracellular ATP content, the plates from the 
NeuriTox assay were multiplexed with an ATP assay, i.e., 
after the image analysis on a Cellomics CellInsight, cells 
were lyzed within the plates. Then, ATP was measured lumi-
nometrically, using a commercial reagent mix (Promega 
CellTiterGlo 2.0) containing luciferase. Data were normal-
ized to DMSO solvent control.
Quantification of aspartate and serine
Amino acids were quantified as described earlier (Delp 
et al. 2018a; Secker et al. 2018). Briefly, cells were lyzed 
on ice with 50% MeOH/H2O and the lysates were vacuum 
dried. After reconstitution in 2% (w/v) 5-sulfosalicylic acid/
H2O (SSA), followed by a centrifugation step (20,000×g, 
30 min, 4 °C), samples were subjected to a HPLC separa-
tion. For detection, a post-column ninhydrin reaction was 
employed that generated colorimetrically detectable amino 
acid derivatives that were quantified by their absorbance at 
570 nm. To determine amino acid concentrations in the cell 
culture medium, samples from the cell culture supernatant 
were obtained. SSA was added to yield a final SSA con-
centration of 2%. Then, samples were centrifuged (30 min, 
4 °C, 20,000×g) and the supernatant was mixed 1:1 with 
sample dilution buffer (0.12 M LiCl, pH 2.2) and analyzed 
as described above.
Assessment of neurotoxicity in SH‑SY5Y cells
Human neuroblastoma SH-SY5Y cells were plated in 
96-well plates with micro-clear bottom (31,250 cells/cm2, 
Greiner) in 100 µl proliferation medium (EMEM supple-
mented with 10% fetal bovine serum, 2 mM l-glutamine, 
1% non-essential amino acids, 100 µg/ml streptomycin 
and 100 U/ml penicillin) (Gustafsson et al. 2010). Differ-
entiation was initiated 24 h later (on day 0) by exchange 
to 100 µl/well differentiation medium (DMEM:F12, sup-
plemented with 1 µM all-trans retinoic acid (RA), 1 × N2 
supplement, 2 mM l-glutamine, 100 µg/ml streptomycin 
and 100 U/ml penicillin). All media and supplements were 
obtained from Gibco (ThermoFisher) except from RA 
(Sigma). On d3, 50% of the medium was exchanged. Con-
ventional SH-SY5Y cultures (Glc-SH-SY5Y cells) received 
fresh differentiation medium on d6, together with the toxi-
cant. Cell cultured in Gal medium (Gal-SH-SY5Y cells) 
received fresh Gal-differentiation medium (AdvDMEM/
F12, supplemented with 1 µM RA, 2 mM l-glutamine and 
18 mM galactose (Roth) instead of glucose) on d5 to allow 
metabolic adaptation. The cells were exposed to toxicants 
on d6. Test compounds were always added in 10 µl of 10 
× concentrated test substances for 24 h. Subsequently, 
cells were stained with 5 µg/ml H-33342, and 5 µM pro-
pidium iodide (PI, Sigma) (final concentrations) to assess 
cell viability, i.e., the fraction of non-PI positive cells (live 
cells) relative to H-33342 positive cells (total cell count) 
by automated high content microscopy [ImageXpress 
Micro (Molecular Devices, UK)]. The cells were imaged 
using a 10 × objective lens, and the following wavelengths: 
H-33342 excitation 377 ± 50 nm, emission 447 ± 60 nm, 
100 ms exposure time, PI excitation 562 ± 40 nm, emission 
624 ± 40 nm, 400 ms exposure time.
Curve fitting, data mining and statistics
For all data shown, at least three independent experiments 
were performed. Each independent experiment (= biologi-
cal replicate) consisted of several technical replicates. In the 
first data processing step, data of the technical replicates 
were expressed as percent of their respective solvent controls 
within a biological replicate. After that, technical replicates 
were averaged, i.e., the mean of all technical replicates of 
one independent experiment was used as single data point 
of a biological replicate. Subsequently, the mean of the ≥ 3 
biological replicates was determined, and a measure of vari-
ation (SD/SEM) was calculated.
Curve fits were calculated using a four-parameter Hill 
model with constraints for the upper asymptote to 100% 
of solvent-treated samples. The equation of the Hill model 
was solved for f(x) = 75% or 50% to determine the  EC25 
or  EC50, respectively, i.e., the concentration at which the 
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neurite outgrowth inhibiting effect was at 25% or 50% of 
the solvent control. If not stated otherwise, data in the fig-
ures are mean ± SEM and statistical differences between the 
treatments and the control were evaluated by an analysis 
of variance (ANOVA) followed by Dunnett’s post hoc test 
(p < 0.05).
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Results and discussion
Comparison of basic metabolic, morphological 
and functional features of cells cultured in glucose 
vs galactose
The most important sugar for cellular energy supply is 
glucose (Glc), but most cells express transporters and a 
metabolic machinery to use related carbohydrates. One of 
these is galactose (Gal), the C4 epimer of glucose. Gal and 
Glc are nearly identical molecules, differing only in the 
stereospecific conformation of the hydroxyl group at carbon 
atom 4 (Fig. 1a).
For energy production, all sugars are converted to one of 
the canonical glycolysis intermediates, and from this stage 
on, they all follow the same unified pathway to form pyru-
vate (Pyr). Gal metabolism (galactolysis) differs from Glc 
metabolism (classical glycolysis) only in the entry steps. 
Glc is directly (single enzymatic step) converted to glucose-
6-phosphate (G6P), the first glycolytic metabolite; the con-
version of Gal to G6P requires three enzymatic steps, plus 
a recycling reaction, i.e., the co-ordinate function of four 
enzymes. However, contrary to erroneous reports in the lit-
erature, the conversion of Glc and Gal to G6P requires the 
same amount of energy (i.e., one ATP per sugar). If galactol-
ysis and glycolysis produce different amounts of ATP, then 
this must be for kinetic reasons, i.e., because of a different 
flux/speed of the final Pyr formation. Galactolytic turnover 
may be attenuated either due to slower import of Gal, or a 
less rapid conversion to G6P. The theoretical maximal yield 
of reducing equivalents (NADH) and energy equivalents 
(ATP from glycolysis and mitochondrial metabolism) is the 
same for the two sugars (Fig. 1b).
To test the effect of Gal vs Glc supply to neurons, the 
established NeuriTox test protocol was modified. In a paral-
lel experimental setup, starting with the same proliferating 
culture, LUHMES cells were either differentiated in Glc or 
Gal-containing differentiation medium to allow a full adjust-
ment to the metabolic conditions at the time of the toxicant 
treatment (i.e., on d2 of differentiation, after replating). Neu-
rite outgrowth and general cell viability were assessed after 
24 h of treatment for both assay conditions (Fig. 1c).
We expected that cells would use different strategies of 
ATP production, when cultured in Glc vs Gal, as described 
earlier for non-neuronal cells. Our assumption was that cells 
in Glc generate most of their ATP as well as some metabo-
lites like serine and ribose from glycolysis. The abundant 
NADH and pyruvate generated by this metabolic condition 
are transformed to lactate, which is then secreted, and to 
 NAD+ which allows cells further glycolytic flux. Mito-
chondrial metabolism, e.g., the citric acid cycle (TCA), is 
not primarily used for energy production (Fig. 1d). For Gal 
cells, we expected a shift towards a mitochondria-domi-
nated metabolism. Under such conditions, the Pyr produced 
through galactolysis is used to fuel the TCA and thus res-
piratory generation of ATP. With a predominantly mitochon-
drial fate of Pyr, lactate excretion would not be required, and 
less carbon may be used for biosynthesis. Instead, galac-
tolytic NADH would be transported into the mitochondria 
via the malate/aspartate shuttle to produce energy. Increased 
levels of oxaloacetate, formed from pyruvate by pyruvate 
carboxylase (PC), can increase the mitochondrial/cytosolic 
exchange of NADH. PC is known to be active in LUHMES 
cells (Delp et al. 2018a) and to be activated by acetyl-CoA, 
Fig. 1  Theoretical background and experimental conditions for sub-
stituting glucose by galactose. a Structural representations of the two 
hexose C4-epimers glucose (Glc) and galactose (Gal). Both the open 
chain (aldehyde) and the cyclized (pyranose hemiacetal) forms dif-
fer in the position of their C4 hydroxyl group. b Metabolic pathways 
for the catabolism of both sugars. While Glc becomes directly phos-
phorylated by hexokinase (HK) to glucose-6-phosphate (G6P), Gal 
is metabolized through the Leloir pathway to G6P. The Gal metabo-
lism starts with the phosphorylation of Gal to galactose-1-phosphate 
(Gal1P) by galactokinase (GALK). In the next step, Gal1P reacts 
with UDP-glucose to G6P plus UDP-galactose, catalyzed by galac-
tose-1-phosphate uridylyltransferase (GALT). The UDP-galactose 
is recycled back, without energy expenditure, to UDP-glucose by 
UDP-glucose 4-epimerase (UDP-GALE). The generation of G6P via 
either pathway requires energy substrates equivalent to one ATP. The 
downstream reactions leading from G6P to pyruvate (Pyr) are for-
mally identical for Glc and Gal. However, it has been shown for vari-
ous cell types that overall glycolysis proceeds faster than galactoly-
sis, and that the surplus NADH generated from Glc is preferentially 
reacting with Pyr to form lactate (Lac). The NADH formed during 
galactolysis appears to be preferentially used for cellular biosynthesis 
or for full oxidation within mitochondria. c Differentiation scheme of 
LUHMES cells cultured for the Glc–Gal–NeuriTox assay. LUHMES 
cells are kept proliferating in bFGF-containing proliferation medium 
with 18 mM Glc. Differentiation was initiated by placing the cells in 
differentiation medium with either 18 mM Glc (standard Glc setup) 
or 18 mM Gal (galactose setup). On d2 of differentiation, cells were 
detached and replated in medium with the same sugar as before. 
GDNF and cAMP were added to the differentiation medium from 
d0 to d2, but not for d2–d3. One hour after replating, the cells were 
treated with toxicants. After 24 h, the cells were analyzed for neur-
ite outgrowth and viability by automated high content imaging. Vis-
ualization of the different pathway usage assumed to occur in cells 
cultured with Glc (d) vs Gal (e). Hexoses can be metabolized to Pyr 
with the primary objective to enter Pyr as well as the excess NADH 
into the mitochondria to generate ATP via the mitochondrial respira-
tory chain (MRC) activity. Alternatively, sugars may be converted to 
other cellular metabolites, such as serine (Ser) and lactate, without 
ever entering the mitochondria. In this case, all/most ATP required by 
the cells would need to be generated by a high glycolytic flux. d It is 
assumed that cells grown in Glc predominantly use the second vari-
ant of metabolism. The citric acid cycle (TCA) would be used only 
to a minor extent. e Cells cultured in Gal are assumed to use galac-
tolysis to a small extent to generate Lac, ATP, and other metabolites. 
The predominant fate of Pyr would be to feed the TCA to generate 
ATP + CO2. The excess NADH (not used for Lac synthesis) would 
be channeled to the mitochondria as further fuel for the MRC for the 
generation of ATP. An increased flux of NADH to mitochondria via 
the malate/aspartate shuttle would be facilitated by the generation of 
oxaloacetate (OA) from Pyr
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i.e., a metabolite likely to be increased in Gal cells (Yu et al. 
2009). Thus, mitochondria are expected to serve as the main 
source of ATP production in cells cultured in Gal, and this 
may alter cellular sensitivity to mitochondrial toxicants 
(Fig. 1e).
To assure that the expected metabolic changes did not 
alter the overall phenotype, cells cultured in Glc vs Gal were 
characterized extensively on a morphological and functional 
level. Major cytoskeletal structures were chosen to charac-
terize cellular morphology and neurite growth qualitatively. 
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No obvious differences were observed for LUHMES cells 
cultured for 72 h in Glc or Gal (Fig. 2a). To obtain fully 
quantitative data, the outgrowth of neurites, on d2 (before 
re-seeding) and d3 (24 h after re-seeding, regular NeuriTox 
assay endpoint) of cells differentiated in Glc or Gal, was 
measured. No statistically significant difference between the 
parallel replicates was found (Fig. 2b). We also evaluated 
whether the cells adapted their metabolism as expected. Gal 
cells contained/produced more intracellular aspartate (even 
to a degree to export it (Suppl. Item 2)), which would sup-
port the Mal/Asp shuttle. They also contained less serine, a 
typical spin-off metabolite from glycolysis. These changes 
were in accordance with a shift from a glycolytic to a mito-
chondrial metabolism (Fig. 2c), possibly supported by the 
use of extracellular Ser from the medium for biosynthetic 
purposes or glycolysis (Suppl. Item 2).
It was important to verify that the two different metabolic 
situations both allowed LUHMES cells sufficient ATP pro-
duction. We found that both cultures had the same intracel-
lular ATP levels (Fig. 2d). To get a more direct measure 
of differential mitochondrial activity, we measured cellular 
oxygen consumption rates (indicating mitochondrial activ-
ity). As a measure of glycolytic activity, extracellular acidifi-
cation rates (indicating mainly lactate secretion) were quan-
tified. As expected, the basal respiration was doubled in Gal 
cells compared to normal Glc cells. Notably, the maximally 
possible mitochondrial respiration was not significantly 
affected by the Glc–Gal exchange. The Gal cells exploited 
their available respiratory chain function to a higher extent, 
and had accordingly a much lower mitochondrial spare res-
piratory capacity (Fig. 2e).
Vice versa, the basal glycolytic rate of Gal cells was only 
about 50% of that found under Glc conditions. We also tested 
how far glycolysis could be further accelerated under condi-
tions of maximum demand. In Glc cells, this situation was 
simulated by inhibition of all residual mitochondrial ATP 
generation (block by oligomycin). The cells only slightly 
(< 25%) increased ECAR under this condition, suggesting 
that glycolysis was already running maximally. In Gal cells, 
a maximum pull of Pyr to mitochondria was generated by 
uncoupling (FCCP). This also did not increase ECAR largely 
(< 25%) and it indicated that Gal cells fully used the maxi-
mal glycolytic flux possible under the respective Gal sup-
ply (Fig. 2f). Finally, the differences in Lac secretion were 
assessed directly by measurement of extracellular levels of 
lactic acid over time. The lactate secretion rate of Gal cells 
was only 14% of that measured in Glc cells (Fig. 2g).
Increased sensitivity of Gal neurons for toxicity 
of the complex I inhibitor rotenone
To test whether the metabolic shift (Glc–Gal) affected the 
toxicity of mitochondrial inhibitors, the well-established 
complex I (cI) blocker rotenone was used. Concentra-
tion–response data for cell viability were obtained and the 
Glc–Gal exchange resulted in a drastic shift in sensitivity 
of neurons to rotenone of about three orders of magnitude 
(Fig. 3a). Other parameters of cellular function were even 
more dramatically affected by the sugar exchange. Intracel-
lular ATP levels decreased to 50% of control at 5 nM (Gal) 
and at 30 µM (Glc), i.e., with a 6000-fold shift (Fig. 3b). 
Neurite outgrowth (neurite area) also showed a massive shift 
between Glc and Gal and was in both cases affected at lower 
concentrations than viability (Fig. 3c). As additional func-
tional parameter, we measured proteasomal activity. In neu-
rons, this cellular function is impaired when mitochondria 
are dysfunctional and ATP levels drop (Gutbier et al. 2018b; 
Terron et al. 2018). We found here that proteasome activity 
was indeed affected in a similar way as ATP levels, with an 
Fig. 2  Comparison of basic morphological and metabolic features of 
cells cultured in glucose vs galactose. a Differentiated (d3) LUHMES 
cells cultured for 72  h in either glucose- or galactose-containing 
medium showed no morphological differences as assessed by staining 
of nuclei (H-33342) neuronal β-III-tubulin (Tuj1-antibody) and actin 
(fluorescent phalloidin). Representative images, image width 625 µm 
in upper row and 185  µm in lower row. b The neurite area per life 
cell was compared for Gal cells vs Glc cells on d2 (directly before 
trypsinization), or on d3 (24 h after trypsinization and replating). Dif-
ferences were tested for statistical significance by two-way ANOVA 
(sugar × time), followed by Tukey’s post hoc test. Each point repre-
sents one biological replicate, n.s. not significant. c The intracellular 
contents of the amino acids L-aspartate (Asp) and l-serine (Ser) were 
measured in Glc and Gal cells. They were normalized to cell count, 
and then the ratio of the conditions was calculated. Upward bars indi-
cate that the respective metabolite was more abundant in Gal cells. 
Differences in absolute intracellular amino acid concentrations were 
tested for statistical significance by two-way ANOVA (sugar × amino 
acid), followed by Sidak’s post hoc test. Each point represents one 
biological replicate, *p < 0.05. d Intracellular ATP was determined 
in Gal cells and compared to Glc cells, either on d2 (before trypsini-
zation), or on d3 (24 h after trypsinization and replating). Data were 
normalized to the respective cell numbers. Differences were tested for 
statistical significance by two-way ANOVA (sugar × time), followed 
by Tukey’s post hoc test. Each point represents one biological repli-
cate, n.s. not significant. e The oxygen consumption rate, a measure 
for mitochondrial activity, was determined for d3 Glc and Gal cells. 
Basal respiration was assessed in untreated cells, while maximal 
respiration was assessed as described in methods. The respiratory 
reserve capacity was calculated as the difference between maximal 
and basal respiration. Differences were tested for statistical signifi-
cance by unpaired multiple t testing, followed by Sidak–Bonferroni 
multiple testing correction. Each point represents one biological rep-
licate, *p < 0.05. f Extracellular acidification, a measure for glycolytic 
activity, was determined for d3 Glc and Gal cells. Basal acidification 
was assessed in untreated cells, while maximal respiration as detailed 
in methods. Differences were tested for statistical significance by 
unpaired multiple t testing, followed by Sidak–Bonferroni multiple 
testing correction. Each point represents one biological replicate, 
*p < 0.05. g Lactate secretion by Glc and Gal cells was assessed 
enzymatically and normalized to cell count. Differences were tested 
for statistical significance by an unpaired, two-tailed t test, each point 
represents one biological replicate, *p < 0.05
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about 1000-fold offset between Glc and Gal cells (Fig. 3d). 
To separate non-specific toxicants from specific neuro-
toxicants in the NeuriTox test, the ratio of concentrations 
affecting neurite outgrowth and viability [e.g.,  EC25(V)/
EC25(NA)] is calculated. If the ratio is ≥  4, the toxicant is 
considered to be a specific neurotoxicant (Delp et al. 2018b; 
Krug et al. 2013). Under Glc and Gal conditions, rotenone 
exceeded that threshold strongly (Fig. 4a). The data obtained 
with rotenone suggest that the Glc–Gal assay can be trans-
ferred to LUHMES neurons to detect mitotoxicants more 
sensitively and to better separate specific neurofunctional 
effects from plain cytotoxicity. 
Effect of a Glc–Gal exchange on neurotoxicity 
of diverse complex I inhibitors
To further evaluate the assay for its sensitivity to mitochon-
drial toxicants, a broader panel of cI inhibitors was tested. 
We determined for all compounds the  EC25 for inhibition of 
neurite outgrowth  (EC25(NA)) and for general cell viabil-
ity  (EC25(V)). From these data, we determined the ratio of 
 EC25(V)/EC25(NA) as measure for specific neurotoxicity. In 
addition, we visualized for each parameter (V, NA) the shift 
due to the Glc–Gal exchange. For the five additional inhibi-
tors tested (deguelin, fenazaquin, fenpyroximate,  MPP+ and 
pyrimidifen), Gal cells were always much more sensitive 
for neurite damage than Glc cells (Fig. 4b–f). The same was 
observed for viability, with exception of  MPP+. The cells 
were not killed by the compound. It was shown earlier that 
immature LUHMES (d0) are resistant to  MPP+ (Efremova 
et al. 2015; Schildknecht et al. 2009), while the system 
became extremely sensitive after d5 (Krug et al. 2014; Poltl 
et al. 2012). The cells upregulate the dopamine transporter 
(DAT), which is required for  MPP+ toxicity, at d2–3 (Scholz 
et al. 2011) and the amount of toxicant entry may not be suf-
ficient to kill, but only to affect the more sensitive neurites. 
For all five compounds, Gal also increased the  EC25(V/NA) 
Fig. 3  Increased sensitivity of neurons for toxicity of the complex 
I inhibitor rotenone. LUHMES cells were differentiated for 48  h in 
either glucose (Glc, brown) or galactose (Gal, green) containing 
medium. After replating, the cells were treated with increasing con-
centrations of the mitochondrial respiratory chain (MRC) complex I 
(cI) inhibitor rotenone for 24 h, in the same medium. a The cell via-
bility was assessed by calcein/H-33342 staining. The relative number 
of live cells (amongst all cells) is indicated. The red arrow indicates 
the left shift (offset) of the  EC50, caused by a switch from Glc to Gal 
in the assay medium. b–d Different parameters of cellular function 
were assessed in the same experiment in parallel plates. Vertical lines 
were included for easier visual comparison. They indicate the concen-
tration of rotenone that reduced ATP levels by 50%. The curves were 
fitted through the data points derived from five independent experi-
ments. As the concentration spacing was not the same for all experi-
ments, the data points shown are averages from 1 to 5 of these experi-
ments. Different N numbers for the data points were considered in the 
fitting procedure. Differences of rotenone-exposed cells vs control 
were tested for statistical significance by one-way ANOVA, followed 
by Dunnett’s post hoc test. The colored horizontal lines indicate 
the range of conditions that showed statistically significant effects, 
*p < 0.05 (color figure online)
▸
1595Archives of Toxicology (2019) 93:1585–1608 
1 3
Fig. 4  Effect of a Glc–Gal exchange on neurotoxicity of diverse com-
plex I inhibitors. A diverse set of mitochondrial respiratory chain 
(MRC) complex I (cI) inhibitors was tested for neurotoxicity haz-
ard. LUHMES cells were pre-differentiated for 48 h in either glucose 
(brown)- or galactose (green)-containing medium and replated on 
d2. One hour later, the cells were treated with the indicated concen-
trations of the toxicants for 24  h. a Chemical structure of rotenone 
and the ratio of  EC25(viability)/EC25(neurite area), i.e., the index 
for selective neurotoxicity (vs unspecific cytotoxicity) in either Glc 
or Gal medium. b–f For each compound, the upper graph compares 
the relative amount of live cells (general viability) for Glc and Gal 
medium; the lower graph gives the respective data for neurite out-
growth (quantified as neurite area on d3) from the same plates. In 
between, the neurite specificity ratios are indicated.  EC25 values were 
calculated from a four-parameter Hill function. A measure for  EC25 
uncertainty was not obtained. The curves were fitted through the data 
points derived from 3 to 5 independent experiments. As the concen-
tration spacing was adjusted between the experiments, individual data 
points are from 1 to 5 replicates (color figure online)
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ratio compared to the standard NeuriTox assay in Glc. Thus, 
the encouraging results obtained for rotenone were fully con-
firmed by the data from other cI inhibitors.
Effect of a Glc–Gal exchange on neurotoxicity 
of diverse complex II–V inhibitors, uncouplers 
and non‑mitochondrial toxicants
Since mitotoxicants might not only affect cI, a set of cII, 
cIII, cIV and cV inhibitors, as well as uncouplers and non-
mitochondrial toxicants was investigated. For cIII inhibi-
tors (antimycin A, fenamidone, picoxystrobin and pyraclos-
trobin), the Glc–Gal exchange resulted in the same shift of 
sensitivity as observed with cI inhibitors (Fig. 5a–d), and 
the  EC25(V/NA) ratio increased. Under these conditions 
(Gal), cIII inhibitors were specific neurotoxicants with the 
sensitivity of neurites being ≥ 4 higher than the sensitivity 
of overall viability.
For few cII inhibitors (carboxine and thifluzamide), Gal 
increased the sensitivity and neurite specificity, but the off-
set effects were less drastic. In the presence of Gal, two cII 
inhibitors became neurite specific (ratio ≥ 4) (Fig. 5e, f). The 
inhibitor atpenin A5 showed a high specificity in Glc and 
Gal conditions, but was not more potent in the presence of 
Gal, and flutolanil was neither enhanced, nor specific at any 
condition (not shown).
The two investigated cIV inhibitors azide and cyanide 
also displayed a higher toxicity, if the cells were cultured 
in Gal conditions (Fig. 5g, h). For azide, the  EC25(V/NA) 
ratio increased to 22, while cyanide was at best borderline 
neurotoxic under Gal conditions (ratio 3.4).
The cV inhibitors also showed a heterogeneous response 
pattern: Gal cells were more sensitive to 1-octylguanidin 
and oligomycin than Glc cells, but sensitivity of general cell 
viability increased stronger then the sensitivity of the neu-
rite outgrowth (Fig. 6a, b). A similar pattern was observed 
for the two uncoupling substances 2,4-dinitrophenol and 
FCCP (Fig. 6c, d). The activity of cV and the associated 
tightness of the inner mitochondrial membrane for protons 
are vital for proper mitochondrial function, but they are not 
part of the electron transfer process of the MRC. Our results 
suggest that the core parts of the MRC [cI, cIII, (cIV)] are 
more affected by Glc–Gal exchange than other mitochon-
drial functions. Complex II takes a special role, as it belongs 
to the classical MRC, but is for many metabolic situations 
rather a minor side entry. Besides the MRC function, it takes 
its major role as succinate dehydrogenase in the citric acid 
cycle.
To test the argument that the Glc–Gal shift specifically 
affects inhibitors of the MRC, we also tested toxicants with 
non-mitochondrial mode of action. As exemplary toxi-
cants, a proteasome and a Rho kinase pathway inhibitor 
(bortezomib and narciclasine) were selected and tested. For 
both substances, the Glc and Gal concentration–response 
curves were similar (neurite outgrowth as well as viability) 
(Fig. 6e, f). For bortezomib, which is not a central nervous 
system neurotoxicant, the low  EC25(V/NA) ratio was not 
significantly affected by Gal. Narciclasine is a specific neu-
rotoxicant (Delp et al. 2018b; Krug et al. 2013), with a large 
 EC25(V/NA) ratio. This was confirmed in the Gal condition.
The results indicate that the Glc–Gal assay can be used to 
screen substances in medium- to high-throughput screening 
for potential neurotoxicity and for a liability to affect the 
MRC. A single operator can handle 20–30 compounds per 
week to produce concentration–response data. This equals 
400–600 data points, assessed in technical triplicates.
Since the LUHMES-based Glc–Gal assay is to our 
knowledge the first shift assay for neuronal cells, we were 
interested whether it may be transferred to other neuronal 
cultures. We chose SH-SY5Y cells, the most frequently 
used human neuronal cell line in in vitro toxicology as the 
alternative test system. The cells were differentiated for 
5 days in Glc medium and then either kept in Glc until the 
end of the assay, or they were changed to Gal medium, and 
allowed to adapt metabolically for 24 h. Subsequently, Glc 
and Gal cells were treated for 24 h with toxicants (from d6 to 
d7) and thereafter cell viability was measured (Suppl. Item 
3A). Three cI (rotenone, deguelin, tebufenpyrad) and two 
cIII inhibitors (antimycin A and pyraclostrobin) were inves-
tigated at a pre-determined concentration (10 µM) for their 
increase in toxicity in Glc vs Gal. These five substances were 
non-toxic (viability reduction by < 5%) in Glc conditions, 
due to the relatively high tolerance of the neuroblastoma 
cells to the neurotoxicants (Tong et al. 2017). The exchange 
to Gal as main sugar source in the medium, resulted in a 
significant increase in toxicity, i.e., viability was reduced by 
15–35% of control (Suppl. Item 3B). These preliminary data 
suggest that the Glc–Gal-shift assay could be transferred to 
other neuronal test systems. However, it has to be mentioned 
that LUHMES cells tolerated the Gal conditions much better 
Fig. 5  Effect of a Glc–Gal exchange on neurotoxicity of diverse com-
plex II, III and IV inhibitors. A diverse set of mitochondrial respira-
tory chain (MRC) complex II–IV (cII, cIII, cIV) inhibitors was tested 
for neurotoxicity hazard. LUHMES cells were pre-differentiated 
for 48  h in either glucose- (brown) or galactose (green)-containing 
medium and replated on d2. One hour later, the cells were treated 
with the indicated concentrations of the toxicants for 24 h. For each 
compound, the upper graph compares the relative amount of live cells 
(general viability) for Glc and Gal medium; the lower graph gives the 
respective data for neurite outgrowth (quantified as neurite area on 
d3) from the same plates. In between, the neurite specificity ratios are 
indicated. a–d Described cIII inhibitors, e, f described cII inhibitors, 
g, h described cIV inhibitors.  EC25 values were calculated from a 
four-parameter Hill function. A measure for  EC25 uncertainty was not 
obtained. The curves were fitted through the data points derived from 
3 to 5 independent experiments. As the concentration spacing was 
different between the experiments, the data points shown are averages 
from one 1–5 experiments (color figure online)
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than the SH-SY5Y cells. LUHMES cells could easily be kept 
in Gal medium for more than 9 days without any increase in 
cell death compared to Glc conditions (not shown), whereas 
SH-SY5Y cells poorly tolerated culturing in Gal medium 
for > 48 h (fragile neurites, altered morphology; not shown).
This difference in human cell lines could be due to differ-
ent expression patterns of transporters and enzymes required 
for Gal metabolism. Alternatively, cells may differ in their 
ability to increase mitochondrial metabolism in the TCA or 
MRC, as e.g., the malate/aspartate shuttle may have different 
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limitations. Under sub-optimal metabolic conditions, cells 
would perceive Gal not as an alternative energy substrate, 
but as a starvation medium. We conclude that the setup of 
the Glc–Gal shift assay in other neuronal cells will require 
careful examination of their metabolic suitability, and fine 
tuning of the exposure scheme may be necessary to allow 
clear and robust results.
Confirmation of the mode of action (MoA) of test 
substances by direct assessment of mitochondrial 
respiratory chain (MRC) inhibition
The Glc–Gal NeuriTox assay obviously detected some com-
pounds as potential MRC inhibitors (strong Glc–Gal shift), 
but a secondary assay with an independent endpoint would 
be desirable for confirmation of hits, and for exclusion of 
false positives. Therefore, we used LUHMES cells to imple-
ment tests for inhibition of selected mitochondrial targets 
(Salabei et al. 2014). As a rational for these tests, the fol-
lowing background information is important: (1) eukaryotic 
cell membranes can be selectively permeabilized (e.g., with 
digitonin) to deliver respiratory substrates to the mitochon-
dria, without adversely affecting MRC function; (2) selective 
substrates for each of the MRC complexes I–IV are avail-
able; (3) if a more terminal MRC complex (cIII or cIV) of 
the MRC is directly fed electrons, the respective upstream 
complexes are not required for oxygen consumption; (4) tool 
compounds inhibiting cI–IV are available and can be used 
serially to analyze different mitochondrial functions within 
one experiment (Fig. 7a).
Based on these conditions, a two-tiered screening 
approach was developed to identify the mitochondrial target 
complex for potential neurotoxicants. In the first tier, com-
plex I–III activity was assessed. In brief, specific cI substrates 
were used to assess cI activity. Subsequently, cI was inhibited 
and cII substrates were injected. Then, cII was blocked and 
selective substrates were injected to probe the activity of cIII. 
In the second tier, cIV was assessed by inhibition of cI and 
cIII and injection of a cIV substrate (Fig. 7b).
Exemplary data on MRC complex activity of mitochon-
dria treated with highly specific tool compounds indicate the 
good performance of this test strategy (Fig. 7c). Complex I 
(rotenone) and cII inhibitors (3-nitropropionic acid) reduced 
selectively cI and cII activity, while the other complexes 
were not affected. The cIII inhibitor antimycin A did not 
affect complex IV activity, and caused a strong cIII inhibi-
tion. However, block of the electron flow at cIII lead to an 
apparent inhibition of cI and cII, since substrates feeding 
into these complexes could not deliver their electrons to cIV, 
and thus they did not promote oxygen consumption (Suppl. 
Item 4). The same was observed for the cIV inhibitor azide 
which led to an apparent cI–III inhibition. These inhibition 
patterns, due to the use of OCR as common endpoint for 
all MRC activity assays, were taken into account for the 
data evaluation algorithm (Fig. 7d). For the cV inhibitor 
oligomycin, which causes an accumulation of protons in 
the intermembrane space, an apparent inhibition of cI–IV 
was observed. Inhibition of cI activity was strongest, since 
electrons fed into the MRC via cI cause most protons to be 
pumped across the inner mitochondrial membrane (5 pro-
tons per electron, or 20 protons per  O2 finally consumed). 
Electrons fed into the MRC via cII or cIII cause the trans-
location of 12 protons per  O2 finally consumed, while an 
electron fed into the MRC via cIV causes the translocation 
of only 1 proton (4 electrons per  O2 consumed). Therefore, 
the proton gradient-based resistance decreased with proxim-
ity to cIV. The uncoupler FCCP did not affect OCR driven 
by substrates of cII–IV. However, it increased apparent cI 
activity relative to control. By uncoupling the mitochondrial 
membrane, the proton gradient physiologically established 
to allow cV activity (ATP synthesis) was removed. Thus, cI 
worked against less resistance when pumping protons across 
the mitochondrial membrane.
The knowledge about the serial connection of the individual 
MRC complexes and the typical inhibition patterns of tool 
compounds lead to the development of a decision model that 
translates the assay data into a MoA classification (Fig. 7d). 
Note that the classification model uses the data in a different 
order than the electron flow through the MRC. This is due to 
the necessity to take upstream/indirect effects into account.
This screening and decision strategy was applied for 25 
compounds to investigate their proposed MoA (Suppl. Item 5). 
For all described and tested cI inhibitors (7), a selective cI inhi-
bition was confirmed. For four of five cII inhibitors, a selective 
cII inhibition was confirmed. Mepronil rather behaved like a 
mixed/cIII inhibitor and the discrepancy with the original lit-
erature needs to be clarified (FRAC 2011; Mitani et al. 2001; 
Zhang et al. 2009). Antimycin A and three strobins were con-
firmed as cIII inhibitors, while cyazofamid rather displayed 
Fig. 6  Effect of a Glc–Gal exchange on neurotoxicity of other inhibi-
tors (complex V, uncouplers and non-mitochondrial). A diverse set of 
mitochondrial respiratory chain (MRC) complex V (cV) inhibitors, 
as well as uncoupling substances and non-mitochondrial toxicants 
was tested for their neurotoxicity hazard. LUHMES cells were pre-
differentiated for 48 h in either glucose (brown)- or galactose (green)-
containing medium and replated on d2. One hour later, the cells were 
treated with the indicated concentrations of the toxicants for 24 h. For 
each compound, the upper graph compared the relative amount of 
live cells (general viability) for Glc and Gal medium; the lower graph 
gives the respective data for neurite outgrowth (quantified as neurite 
area on d3) from the same plates. In between, the neurite specificity 
ratios are indicated. a, b Described uncouplers, c, d described uncou-
plers, e, f non-mitochondrial toxicants.  EC25 values were calculated 
from a four-parameter Hill function. A measure for  EC25 uncertainty 
was not obtained. The curves were fitted through the data points 
derived from three independent experiments. As the concentration 
spacing was adjusted between the experiments, individual data points 
are from 2 to 3 replicates (color figure online)
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the pattern of an uncoupling substance. Again, differences in 
the original literature (Dreinert et al. 2018; FRAC 2011; Li 
et al. 2014) may be due to technical issues, or have a biological 
basis, as the reference data were obtained with subcellular 
fractions and/or non-human species. Such model dependence 
has been observed earlier for, e.g., thiazolidinediones and 
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statins, which either inhibit several mitochondrial complexes 
or/and uncouple the respiratory chain (Nadanaciva et al. 2007). 
Moreover, uncouplers like FCCP are known to lead to MRC 
inhibition when used at too high concentrations (Senkowski 
et al. 2015).
Substances not described as MRC inhibitors (e.g., colchi-
cine or carbaryl) were clearly classified as such (non-MRC 
inhibitors). Interestingly, one substance (dhmtAc, ID#14) 
identified earlier by us as chemotherapeutic with potential 
neurotoxic side effects (de Souza-Fagundes et al. 2018), was 
found to cause a mixed cI/cIII inhibition, and thus to act as 
typical mitotoxic neurotoxicant.
Enhanced detection of neurotoxicants by the Glc–
Gal shift NeuriTox assay
To determine the assay performance of the Glc–Gal shift 
assay, the training set was expanded to a total of n = 53 
(adjust) substances. They represented different types of 
mitochondrial and non-mitochondrial toxicant classes 
(Fig. 8a, Suppl. Item 1). While specific cIV inhibitors were 
hard to find, many compounds have been described earlier 
to block cI and cIII. Several of these have been optimized 
for pesticide use (Becker et al. 1981; FRAC 2011; Lüm-
men 1998; Nauen and Bretschneider 2002; Sherer et al. 
2007). Our classification of these compounds is based on 
their original description or review literature on this. In this 
context, it is important to note that the uncertainties of clas-
sification differ from toxicant to toxicant. Substances like 
rotenone have a high specificity and have been used and 
confirmed in dozens of studies, while descriptions of other 
compounds may date back many decades, and data on the 
specificity of a mode of action (as opposed to other ones) 
are hard to determine. In a synoptic overview, the literature-
based classification was displayed together with information 
on confirmed mechanisms in the MRC complex assay for a 
subset of compounds (Fig. 8b).
To identify the substances to which cells were more sen-
sitive in the Gal conditions, the  EC25(NA)[Glc/Gal] ratio 
was calculated and color coded. Further on, as measure for 
specific neurotoxicity, the  EC25(V/NA) ratio was calculated 
for both, the Glc and Gal conditions. For many of the tested 
cI–cIV inhibitors, the specificity ratio increased in Gal 
medium. For uncouplers and non-mitochondrial toxicants 
of all modes of action (e.g., cytoskeleton interfering, protea-
some inhibitors, endoplasmic reticulum stressors, and DNA 
damaging agents), the ratios were hardly affected (Fig. 8b, 
c).
Assessing the Glc vs Gal offset in more detail, it gets 
obvious that Gal cells had clearly increased sensitivities to 
all tested cI inhibitors (median offset of 450) and clearly no 
increased sensitivity to all tested non-mitochondrial toxi-
cants (median offset ratio of 1.0) (Fig. 8d). Inhibitors for 
Fig. 7  Confirmation of the mode of action (MoA) of test substances 
by direct assessment of mitochondrial respiratory chain (MRC) inhi-
bition. For the assay, cells and their outer mitochondrial membranes 
(but not the inner mitochondrial membrane) were permeabilized. 
They were otherwise left intact in the culture dishes. Their oxygen 
consumption rate (OCR) was measured in the presence of specific 
substrates and respiration modifiers. a Schematic representation of 
a mitochondrion within a permeabilized cell. The specific substrates 
(electron donors) for individual respiratory chain complexes are 
indicated in green. The complex-specific inhibitors are indicated in 
red. Individual MRC complexes are displayed as pink barrels. Nor-
mally, electrons are fed from NADH into the MRC via cI. They are 
then transported via ubiquinone/coenzyme Q (Q) to cIII and further 
on via cytochrome c (Cyt c) to cIV, which transfers them to the final 
electron acceptor oxygen  (O2). The electrons from  FADH2 are fed 
into the MRC via cII, which also transfers them via Q to cIII. The 
transport of electrons is coupled to pumping of protons over the inner 
mitochondria membrane. This proton gradient drives cV, the mito-
chondrial ATP synthase. FCCP can be used as a tool compound to 
uncouple the mitochondrial membrane, i.e., to allow a proton flux to 
the mitochondrial matrix that bypasses cV, and thus does not con-
tribute to ATP generation. b Workflow and rationale to screen for 
inhibitory effects of toxicants on individual MRC complexes, using 
the Agilent Seahorse XF analyzer for quantification of the OCR. 
Cells were permeabilized manually before they were placed into the 
Seahorse analyzer. Then the basal OCR was assessed, and used for 
internal normalization (cell number/activity correction) between the 
wells. Then, the potential toxicant was injected and one of two screen 
programs (denominated here tier1/tier2) was run. In tier 1, first cI 
activity was assessed. Subsequently, cI was inhibited and a selective 
substrate of cII was added (cII feeding). Further on, cII was inhib-
ited and a selective substrate of cIII was added (cIII feeding). In tier 
2, the complex IV activity was assessed. For this, cI and cIII were 
inhibited and cIV was fed. All toxicant data were compared to solvent 
control (DMSO) and were, after normalization, analyzed applying 
the decision model depicted in d. c Exemplary data sets for six well-
established tool compounds to demonstrate the typical assay perfor-
mance. White bars indicate non-significant effects on the respective 
complex. Black bars indicate the main inhibited complex; gray bars 
indicate that the respiration via the respective complex was signifi-
cantly reduced, but this effect was assumed to be secondary/indirect 
due to the sequential assay conditions shown in b. The light gray 
area indicates the non-significant range of the assay, and was defined 
by × 2 SD of the baseline variation. The error bars for the complex 
inhibition by the compounds are the SEM of  ≥ 3 independent repli-
cates (NPA: 3-nitropropionic acid). d Decision model translating the 
results of the screen (blue boxes) as described in b into a compound 
classification (green hexagons). Note that the experimental scheme 
(sequence of measurements) differs from the data evaluation scheme! 
The latter decision tree starts with the evaluation of cIV data. If cIV-
mediated respiration was impaired (measured in tier 2), the substance 
was classified as cIV inhibitor. If not, data on cIII-mediated respira-
tion were used. If they showed cIII to be impaired, then additional 
data on the effect of FCCP were required. If FCCP increased the cIII-
mediated respiration, the test substance was classified as cV inhibitor, 
while it was classified to be a cIII inhibitor, if cIII-mediated OCR was 
not affected by FCCP addition. Note that the variant of tier 1 ± FCCP 
is not shown in B) for clarity reasons. If cIII-mediated respiration 
was not affected, data on cII- and cI-mediated respiration were used. 
If data indicated that cII-mediated respiration was reduced, the com-
pound was classified as cII inhibitor. If cI-mediated respiration was 
increased by the toxicant, it was classified as an uncoupler; if it was 
decreased, the toxicant was classified as cI inhibitor. If neither cI nor 
cII activity was affected (and also not cIII and IV, as determined ear-
lier), the substance was classified as “no MRC inhibitor” (color figure 
online)
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cIII and cIV had median offset ratios of 17 and 8.1, while 
other toxicants showed largely similar effects in Glc and 
Gal medium.
A clear alert for neurotoxicity was also given for valino-
mycin and salinomycin. Both compounds are described 
to be selective potassium ionophores (Daniele and Holian 
1976; Furlong et al. 1998; Mitani et al. 1975; Naujokat et al. 
2010). This provides a plausible MoA: under physiological 
conditions, the proton motive force (Δp, Gibb’s free energy) 
across the inner mitochondrial membrane, is due to: (1) the 
concentration gradient of  H+ (ΔpH) and (2) the mitochondrial 
membrane potential (ΔΨ). A free potassium transport across 
the mitochondrial membranes (caused by valinomycin) elimi-
nates ΔΨ, while ΔpH is not affected directly. Thus, potassium 
ionophores decrease Δp, but do not completely eliminate it 
(different from classical uncouplers). Since respiration of 
intact cells was increased after valinomycin treatment (not 
shown), these two compounds were classified as uncouplers, 
although their MoA differs from classic  H+ ionophore uncou-
plers. The specificity ratio was increased for valinomycin and 
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salinomycin in Gal medium, confirming the neurotoxicity of 
these compounds. Sensitivity of the cells to the proton iono-
phores CCCP and FCCP, which both rescind the proton (ΔpH) 
and charge (ΔΨ) gradients, was slightly increased in Gal condi-
tions. However, the  EC25(V/NA) ratio was decreased for both 
uncouplers from ≥ 4 in Glc to < 4 in Gal. The comprehensive 
understanding of potential organ (CNS)-specific toxicities of 
such compounds will require further studies.
Among the tested cIII inhibitors, hydramethylnon was the 
only one, for which no sensitivity offset between Glc and Gal 
conditions was observed. Moreover, its  EC25(V/NA) ratio 
was the lowest of all measured cIII inhibitors. Viability and 
neurite outgrowth curves were overlapping and extremely 
steep, which made it technically difficult to quantify small 
changes robustly, and other (non-mitochondrial) MoA can-
not be excluded for this compound.
Conclusions and outlook
Detection and evaluation of neurotoxicity 
and mitotoxicity
In this study, we evaluated the feasibility and useful-
ness of tuning the established NeuriTox assay to detect 
mitochondrial neurotoxicants more sensitively. Culture in 
galactose-containing medium made LUHMES cells meta-
bolically more reliant on mitochondrial metabolism.
The a priori effect of Gal on toxicant sensitivity is 
assumed to be due to a higher dependence of cells on 
MRC function (Marroquin et  al. 2007). Although our 
data are largely consistent with this (Suppl. Items 6, 7), 
detailed mechanistic follow up seems important for two 
reasons: (1) the data do not allow conclusions on whether 
‘mitochondrial function’ refers only to ATP synthesis, 
or whether other processes, such as mitochondrial ROS 
generation (Indo et al. 2007) are also involved; (2) the 
exact analysis of concentration–response curves suggests 
that cell function (neurite outgrowth) may be affected at 
inhibitor concentrations not affecting ATP levels (Suppl. 
Item 6).
Besides galactose, other carbohydrates and metabolic 
modifiers have been used for metabolic reprogramming of 
cells. It is important to note that nearly all of them show 
cell type-specific effects, as they depend on the expression 
patterns of specific enzymes as well as specific metabolic 
need of the respective cells. For instance, fructose can 
be used to shift the cell death program from apoptosis to 
necrosis in hepatocytes, or to protect the liver from TNF 
toxicity in vivo (Latta et al. 2000). It acts by depleting cel-
lular phosphate (and therefore ATP), similarly to the fre-
quently used sugar analogue deoxyglucose (Pietzke et al. 
2014). Mannose acts on certain tumor cells by impairment 
of glycolysis and increases the cytotoxic effects of chemo-
therapy without affecting cellular ATP levels (Gonzalez 
et al. 2018).
Other metabolic modifiers that drastically affect cellular 
apoptosis/necrosis are, e.g., nitric oxide (Leist et al. 1999; 
Volbracht et al. 1999) or the amino sugar galactosamine 
(Gantner et al. 1995; Leist et al. 1995). Also here, cell 
specificities are observed due to the metabolic machin-
ery expressed. Our study shows that LUHMES cells, at 
the developmental stage used for the NeuriTox test, ide-
ally fulfill the requirements for a Glc–Gal shift assay: (1) 
they can use Gal as energy substrate (and survive up to 
9 days in it), and (2) they are metabolically re-programmed 
by Gal to increase mitochondrial contribution to ATP 
generation.
This allowed a more sensitive identification of neuro-
toxicants and mitochondrial toxicants. While the former 
are identified by a ratio of  EC25(V)/EC25(NA) ≥ 4, the lat-
ter can be identified by an increased sensitivity in Gal 
conditions vs Glc conditions [shift in  EC25(NA)]. If the 
threshold for that shift is set to two, mitochondrial toxi-
cants are identified with a sensitivity of 89% (for cI–V 
inhibitors and non-mitochondrial toxicants; n = 39). Toxi-
cants with a MoA that is not primarily related to mito-
chondrial metabolism showed no shift in sensitivity in Glc 
Fig. 8  Synoptic overview of tested substances and their enhance-
ment of neurotoxicity by a Glc–Gal shift. a Overview of all tested 
substances (n = 52) in the Glc–Gal–NeuriTox assay, grouped accord-
ing to their assumed mode of action (MoA). b Detailed tabular over-
view about the tested substances, their toxic potency and their selec-
tive neurotoxicity data (ratios of concentrations that impaired neurite 
outgrowth and viability) in Glc vs Gal media. The column with the 
ratio of  EC25(NA) [Glc/Gal] informs about the increase in sensitiv-
ity when the cells were cultured in galactose. In this column, cells 
were marked red if the ratio was < 1.5 (no enhancement by Gal), 
yellow if it was between 1.5, and 3 and green, if it was > 3 (strong 
toxicity enhancement by Gal). The two columns to the right indicate 
the ratio between the concentrations that caused specific neurite out-
growth inhibition (NA) and unspecific cell death (V). The cells in 
this column were colored blue, if the ratio was ≥ 4. Such compounds 
were considered to be specific neurotoxicants. Small superscripts on 
the compound names indicated results from our mitochondrial com-
plex activity profiling; cI–cIV indicate a classification as inhibitor 
of cI–V, u indicates uncoupling, m indicates a mixed impairment of 
the MRC, o indicates that the substance did not interfere with cI–V 
activity. Cyazofamid was not included in this analysis since it was 
insoluble in the active concentration range. c Enhancement in neuro-
toxicity (= impairment of neurite outgrowth; NA) in Glc (brown) vs 
Gal (green) cells is displayed for all test compounds, subdivided by 
their assumed mode of action. The black lines indicate an enhanced 
neurotoxicity under Gal conditions if they are angled upwards. d The 
data from C are indicated as ratio of Glc (brown)/Gal (green) data 
points, i.e., the enhancement by Gal vs Glc is directly visualized. 
The red horizontal lines indicate the median enhancement within the 
group of compounds, e.g., about 450-fold for the group of cI inhibi-
tors. Median values for cII–V inhibitors, uncoupling and non-mito-
chondrial toxicants are 1.6, 17, 8.1, 6.5, 1.5, 1.0, respectively. MTPB 
methyltriphenylphosphonium bromide (color figure online)
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vs Gal conditions. The test specificity was in this case 
100% for non-mitochondrial substances. This was regard-
less of the fact whether these substances were considered 
to be neurotoxic (e.g., colchicine, narciclasine, brefeldin, 
albendazole) or unspecifically cytotoxic (e.g. MG-132, 
cisplatin).
A major challenge in the field of mitotoxicity remains the 
exact definition and mechanistic understanding of processes 
leading to “mitochondrial toxicity”. The Glc–Gal-shift 
assays as tool to identify neuronal MRC inhibitors has been 
successfully applied here for a neuronal culture. Although 
the new test has proven to be valuable already, important 
questions remain with respect to a broader characterization 
of diverse mitochondrial dysfunctions, e.g., triggered by 
inhibitors of fatty acid oxidation, mitochondrial DNA syn-
thesis, the urea cycle or phospholipid and steroid synthesis.
Our finding that toxicity to cI inhibitors was extremely 
affected by the Glc–Gal shift, while cells were hardly sen-
sitized to cII inhibitors, shows that these MRC complexes 
must take fundamentally different physiological roles and 
thus cause different toxicities. This deserves further atten-
tion, e.g., in the context of AOP development, where the key 
event “mitochondrial dysfunction” (Terron et al. 2018) may 
need to be defined in more detail.
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